INTERACT Meeting Timing Remains Point Of Confusion

 
• By Derrick Gingery
  
ambiguity
The development timing for an INTERACT meeting remains a regulatory gray area. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards